Adams Respiratory kept at sector perform by RBC

RBC Capital Markets analyst Ken Trbovich maintained Adams Respiratory Therapeutics Inc. at sector perform, above average risk, and a $50 price target on news that management remains committed to developing new brands and line extensions of existing products. This is good news, according to the analyst, in light of the abbreviated New Drug Application filed for Mucinex. Strong results are expected during the seasonally strong second and third quarters, compared to past years. Shares of the Chester, N.J.-based pharmaceutical company were down 25 cents, or 0.64%, at $39.05, on volume of 265,484 shares versus the three-month running average of 365,197 shares. (Nasdaq: ARXT)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.